U.S. buyout firm Gores Group is weighing a sale of immunotherapy company Therakos amid a boom in health care deals, according to people with knowledge of the matter. Gores is working with Credit Suisse Group AG on the sale, which may value Therakos at about $1 billion, the people said, asking not to be identified because the process is private. Therakos may attract interest from other buyout firms and health care companies, the people said.
Amgen Inc., the maker of cancer treatments and blood boosters to combat anemia, reported first-quarter profit that topped analysts’ estimates and raised its forecast for the year on stronger-than-expected drug sales. The shares rose in late trading.